Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Overview of Certara, Inc.
Certara, Inc. (symbol: CERT) is a global provider renowned for its biosimulation technology and advanced decision support systems that drive model-informed drug development. Utilizing scientific software and consulting services, Certara empowers biopharmaceutical companies, academic researchers, and regulatory agencies to optimize drug discovery processes and enhance patient care. The company excels in leveraging biosimulation, drug development, and model-informed development techniques to provide robust solutions that transform the way medicines are developed, assessed, and regulated.
Business Focus and Core Offerings
Certara integrates highly specialized simulation software with expert regulatory consulting and technology solutions. Its offerings are designed to streamline various stages of the drug development lifecycle, from early discovery to clinical trial design and regulatory submissions. By bridging complex scientific data and actionable insights, the company assists in reducing the reliance on extensive clinical trials, accelerates regulatory approvals, and enhances patient access to novel therapies.
Advanced Technology and Simulation Capabilities
The company is at the forefront of innovation with its comprehensive suite of software solutions. Certara's offerings include modeling and simulation platforms which incorporate advanced techniques such as quantitative systems pharmacology (QSP) and physiologically-based pharmacokinetics (PBPK). These tools are designed to simulate human physiology and drug interactions, thereby refining dosing strategies and minimizing risk during clinical development phases. The introduction of integrated solutions, such as Certara Cloud, demonstrates the seamless connectivity of different software products, enabling customers to manage licenses, perform detailed analysis, and generate reliable insights within a unified workflow.
Regulatory Science and Consulting Services
Certara's expertise extends into regulatory science and consulting, areas that are critical for navigating the complex frameworks of drug development. By offering detailed regulatory strategies and scientific consulting, the company supports clients in meeting the rigorous requirements of global health authorities. The unique combination of advanced modeling software and regulatory insight helps clients reduce uncertainty and increase the probability of successful regulatory outcomes, offering a significant strategic advantage in the competitive pharmaceutical market.
Market Presence and Competitive Position
Operating across the Americas, EMEA, and Asia Pacific, Certara has cemented its role as a key contributor in the drug development sector. The company’s clientele includes major global biopharmaceutical companies, leading academic institutions, and influential regulatory bodies. Its technology-driven approach to accelerating drug development positions it uniquely within the competitive landscape, providing a robust alternative to traditional clinical trial methodologies and reinforcing its authority in the realm of biosimulation and regulatory strategy services.
Integrated Solutions and Client Benefits
One of the signature aspects of Certara is its integrated platform approach. Products like Certara Cloud offer a centralized portal for accessing multiple software solutions, thus streamlining workflows for users managing diverse aspects of drug development. This integration not only enhances operational efficiency but also provides a scalable and interoperable environment where feedback from users is continually incorporated into the evolution of the company's software suite. By addressing complex drug development challenges with precise and reliable modeling and simulation tools, Certara ensures that scientists and regulators can derive actionable insights more rapidly.
Scientific Expertise and Industry Application
Certara leverages its scientific expertise to address inherent challenges in drug development. The company’s simulation solutions facilitate more informed decision making, improving both the efficiency and safety of clinical trials. Its scientifically advanced models enable the transformation of raw data into strategic insights, thereby streamlining the path from research to patient care. This expertise is critical in an industry where optimizing therapeutic outcomes and meeting regulatory demands are of utmost importance.
Conclusion
In summary, Certara, Inc. stands as a sophisticated confluence of technology, scientific expertise, and regulatory insight. Its comprehensive suite of modeling, simulation, and consulting services provides a concrete foundation for revolutionizing the drug development process. By consistently delivering precise, integrated solutions and employing advanced simulation techniques, Certara plays an instrumental role in bridging the gap between innovative research and the swift, safe delivery of new medicines to patients.
Certara (Nasdaq: CERT) has released Version 24 of its Simcyp™ Simulator, enhancing its physiologically-based pharmacokinetic (PBPK) modeling platform. The update includes significant improvements in biopharmaceutics, drug-drug interactions, and biologics capabilities.
Key updates include enhanced food effect predictions in the Virtual Bioequivalence module, expanded drug-drug interaction libraries, improved biologics modeling, and enhanced trial design support. The platform also features modernized UI, cloud computing capabilities, and AI-enabled assistance.
The Simcyp Simulator, guided by a consortium of over 30 pharmaceutical companies, has contributed to more than 120 FDA-approved novel drugs. Notably, 4 out of 5 drugs using PBPK for FDA approval in recent years utilized the Simcyp Simulator.
Certara (NASDAQ: CERT) has appointed Dr. Adrian McKemey as President of Drug Development Solutions, effective March 3rd, 2025. McKemey, who previously served as head of Enterprise Transformation at IQVIA and Senior VP of R&D Strategy Solutions at Quintiles, brings over 25 years of experience in research and development.
The appointment is part of a planned leadership transition, with Patrick Smith, PharmD, moving to the role of Senior Vice President of Translational Sciences. McKemey holds a BSc and PhD in High Energy Nuclear Particle Physics from the University of London, and previously worked as a Principal at Boston Consulting Group's Life Sciences practice.
The company aims to leverage McKemey's expertise to accelerate growth in its biosimulation and scientific services for life sciences clients globally, focusing on improving drug development processes and portfolio decision-making through in silico models.
Certara (NASDAQ: CERT) reported strong Q4 2024 financial results with total revenue of $100.4 million, up 14% year-over-year. The company's performance was marked by significant growth across segments, with software revenue increasing 26% to $42.3 million and services revenue growing 7% to $58.1 million.
Notable achievements include a net income of $6.6 million, compared to a previous year's loss of $12.5 million, and adjusted EBITDA of $33.5 million, representing 13% growth. Total bookings reached $144.5 million, up 22%, with software bookings growing 38% to $59.7 million.
Looking ahead, Certara provided 2025 guidance projecting revenue between $415-425 million, with adjusted EBITDA margin of 30-32% and adjusted diluted EPS of $0.42-$0.46.
Certara (NASDAQ: CERT) announced it will release its Q4 and full-year 2024 financial results after market close on February 26th, 2025. Management will host a conference call at 5:00 PM ET to discuss the results, with advance registration required for investors.
Additionally, the company's management team will participate in two upcoming investor conferences in March: the Leerink Partners Global Healthcare Conference on March 11th at 1:00 PM ET and the Barclays 27th Annual Global Healthcare Conference on March 12th at 11:30 AM ET. Live and archived webcasts of these events will be available on Certara's investor relations website.
Certara (NASDAQ: CERT) released preliminary Q4 and full-year 2024 financial results, reporting annual revenue of $384.4 million, up 8% from 2023. Q4 revenue reached $99.7 million, showing 13% growth year-over-year.
The company's software segment demonstrated strong performance with Q4 revenue of $41.6 million (+24%) and full-year revenue of $155.0 million (+18%). Services revenue grew more modestly, with Q4 at $58.1 million (+7%) and full-year at $229.4 million (+3%).
Total bookings for 2024 increased 11% to $445.3 million, with software bookings growing 24% to $169.4 million and services bookings up 4% to $275.9 million. The company confirmed its adjusted EBITDA guidance range of $120-124 million for 2024. The results include contribution from Chemaxon, acquired on October 1, 2024, which added $5.9 million in revenue and $11.0 million in bookings.
Certara (CERT), a leader in model-informed drug development, has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to present on Wednesday, January 15th, 2025, at 5:15 PM Pacific Time.
Investors and interested parties can access a live webcast of the presentation through Certara's investor relations website at https://ir.certara.com. The presentation recording will remain available for replay on the website for a minimum of 30 days following the event.
Certara (Nasdaq: CERT) highlights its 2024 research achievements with over 100 publications and recognition of 12 company scientists in the Stanford/Elsevier top 2% cited researchers list. The publications cover diverse areas including pediatric oncology, first-in-human dose predictions, exposure-response analyses, and the application of PBPK modeling in global health. Notable research trends focused on biosimulation strategies in drug development and extended model-informed drug development, including the implementation of generative AI in regulatory writing and diversity in clinical trial enrollment.
Certara (NASDAQ: CERT) reported Q3 2024 financial results with revenue of $94.8 million, up 11% year-over-year. Software revenue grew 15% to $35.9 million, while services revenue increased 9% to $58.9 million. The company posted a net loss of $1.4 million, significantly improved from a $49.0 million loss in Q3 2023. Adjusted EBITDA rose 15% to $33.1 million. Total bookings grew 13% to $96.1 million. The company updated its full-year 2024 guidance, expecting revenue between $380-385 million and adjusted EBITDA of $120-124 million.
Certara (Nasdaq: CERT), a global leader in model-informed drug development, has announced its participation in the Stephens Annual Investment Conference. The company's management will deliver a presentation on Thursday, November 21st, 2024, at 10:00 AM CT. Investors and interested parties can access a live webcast of the presentation through Certara's investor relations website at https://ir.certara.com. The presentation recording will remain available for replay for a minimum of 90 days following the event.
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed John Reynders, PhD, to its Board of Directors, effective October 15, 2024. Dr. Reynders brings over 25 years of experience in the pharmaceutical and tech industries, with expertise in artificial intelligence, data science, and life science.
Dr. Reynders' career highlights include serving as the founding CIO of Moderna, where he led data-sciences capabilities for mRNA therapy design, and as Chief Data Sciences Officer at Neumora. He has also held executive positions at Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly, and Celera.
Certara's CEO, William F. Feehery, PhD, expressed excitement about the appointment, emphasizing the value Dr. Reynders' expertise will bring to the company's ongoing development of transformational software and services for accelerating new medicines and increasing pharma R&D productivity.
FAQ
What is the current stock price of Certara (CERT)?
What is the market cap of Certara (CERT)?
What is the core business of Certara, Inc.?
How does Certara support drug development?
What technology platforms are provided by Certara?
Who are the primary clients of Certara?
How does Certara differentiate itself in the market?
What benefits do clients gain from using Certara's platforms?
